ArticleScientific reports2026
Investigation of the functional hot-spot residues of an enzyme by real-time monitoring of the enzymatic reaction using NMR and computational approaches.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Favipiravir is an anti-influenza prodrug that is metabolized to its phosphoribosylated form, favipiravir-ribofuranosyl-5′-monophosphate (favipiravir-RMP), by human endogenous enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This enzymatic reaction is the rate-determining step in generating the active form of favipiravir, making it important to understand the molecular mechanisms underlying the HGPRT-catalyzed RMP-modification of favipiravir. However, the pharmacokinetics of this reaction have not been fully elucidated, despite X-ray crystallographic studies on the HGPRT-favipiravir complex. Here, we identified functional hot-spot residues in HGPRT that play important roles in the enzymatic conversion of favipiravir to favipiravir-RMP. Real-time monitoring of the HGPRT reaction via ligand-observed solution NMR experiments, biochemical mutagenesis of HGPRT, and computational calculations and molecular dynamics simulations, allowed us to investigate the free binding energetics and structural properties of the interaction between HGPRT and favipiravir-RMP. This powerful hybrid experimental strategy allows the identification of functional hot-spot residues in the enzyme and provide complementary structural biological information. This approach could be universally applicable to investigating drug-protein interaction modes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.